Research at Gies

Gathering Knowledge, Powering Innovation

At Gies Business, we promise our students that an education is just the start – that here they can discover their purpose. Our faculty are at the center of that promise, guiding students to challenge assumptions, to be inventive, and to develop their own style. Our exceptional faculty conduct cutting-edge research that regularly impacts industry and helps business decisions get made.

Gies Business Research Lab

The Gies Business Research Lab is dedicated to supporting Gies faculty in performing groundbreaking research on business decision making. Gies faculty are among the top researchers in the world. We are focused on addressing critical societal needs through the transfer and application of knowledge, and we are committed to fostering industry-leading research than can help organizations and individuals make effective, efficient decisions. Your participation in research helps us create knowledge that can enhance the worldwide reputation of the University of Illinois as a premier research institution and shape the future decision-making practices of businesses and organizations around the world. 

For more information, contact Jen Themanson, Coordinator, at

Margolis Lab

Join Our Research Panel

As part of the Business Research Lab panel, you would be invited to participate periodically in research studies on topics in accounting, organizational management, or marketing. Participating in Gies research is voluntary and can be done on your own schedule, as often as you’d like.
Join our research panel.

Data Science Research Service

The Data Science Research Service (DSRS) drives research within the Gies College of Business by assisting students, faculty, and staff with their data science, machine learning, computational infrastructure, and data acquisition needs. The DSRS works as a component of the Gies Disruption initiative in efforts to make Gies the most technologically-forward and data-capable business college in the world.

For more information, contact Joe Yun at

Research Stories

Value of vaccine to end COVID-19 pandemic worth 5%-15% of global wealth

Nov 23, 2020, 13:53 PM by Aaron Bennett
The monetary value of a vaccine that could potentially end the COVID-19 pandemic is between 5%-15% of worldwide wealth, according to a new paper co-written by Gies Business professor Tim Johnson.

The monetary value of a vaccine that could potentially end the COVID-19 pandemic is between 5%-15% of worldwide wealth, according to a new paper co-written by a University of Illinois Urbana-Champaign business professor.

The value of a vaccine rises substantially when there is uncertainty about the duration of the current pandemic and the likelihood of future outbreaks, said Timothy Johnson, the Karl and Louise Schewe Professor of Finance at Gies College of Business.

“If you had a magic wand that you could wave and make the coronavirus disappear, how valuable would that wand be? In this case, the magic wand is a vaccine, and our bottom-line number was it would be worth between 5%-15% of total wealth,” he said.

The threat of the disease leads to lower labor supply, further harming output and growth.

“Our model is not immunological in that we’re not detailing the dynamics of susceptible and infected populations,” Johnson said. “We’re just modeling the COVID-19 pandemic as something that comes in and destroys wealth and human capital, and then stops at some random, unknown time in the future.”

While the economic benefits of a viable vaccine are undeniably immense, a surprising finding of the paper concerns the contribution to that value from uncertainty, Johnson said.

“The value of the cure rises sharply when there is uncertainty about the frequency and duration of pandemics,” he said. “Simply not knowing whether the virus is going to end in six weeks, six months or six years creates a tremendous amount of, in economic terms, ‘disutility,’ and something that could dispel that uncertainty would be almost as valuable as the cure itself.

“In other words, even if you couldn’t end the current pandemic but you could acquire enough information to know how long it would last, or how long future pandemics would last, you would pay that same order of magnitude of your wealth for that knowledge to resolve that uncertainty.”

Johnson and his co-authors estimated the value of a vaccine – that is, what a “representative agent” would be willing to pay to end the ongoing pandemic – using the joint behavior of stock prices and a novel vaccine progress indicator based on the chronology of stage-by-stage progress of individual vaccine candidates and related news.

The stock market response to news of vaccine progress allowed the researchers to calibrate a model to estimate the economywide financial gain that would be attributable to a cure. To accomplish this, the researchers first needed to summarize the entire corpus of existing vaccine research, spanning several hundred projects worldwide that are racing to develop different versions of a vaccine.

“The state of vaccine research around the world on any given day is very complicated to fully describe if you’re dealing with 200 or so different projects, in terms of their scientific progress and what we know about them,” Johnson said. “So our first task was to try to summarize all of that and shrink it down to one number.

“One of the contributions of the paper is that we introduce a forecasting methodology for a very high-dimensional research endeavor that boils everything down to the one number that we think is most important, which is the expected time to the arrival and deployment of a vaccine. It’s really a statistical approach to the economics of a pandemic, but we think it’s a novel contribution nonetheless.”

From a policy perspective, the implication of the findings are that, while working to end the current pandemic is enormously valuable, equally and perhaps even more valuable is anything that resolves uncertainty about the frequency and, especially, the duration of current and future pandemics, Johnson said.

“In addition to developing cures and vaccines, understanding the fundamental science behind the fight against viral pathogens and investing in the infrastructure for future responses can provide crucial gains to welfare,” Johnson said.

Johnson’s co-authors are Viral V. Acharya and Steven Zheng, both of the Stern School of Business at New York University; and Suresh Sundaresan of Columbia University.

The paper “The value of a cure: An asset pricing perspective” is available online